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BRIAN OLSHANSKY, MD, MEIR MAZUZ, MD, JAMES B, MARTINS, MD 
Iowa City, Iowa 
The frequency of inducible tachycardia was assessed in 
patients presenting with syncope whose noninvasive 
evaluation did not reveal a cause for syncope. It was 
also determined whether treatment of tachyarrhythmias 
during programmed electrical stimulation would pre-
vent recurrence of syncope. One hundred five patients 
were studied and 97 were followed up for a mean period 
of 25.8 months. Sixty-eight patients (65%) did not have 
inducible tachycardia. Sixty of these 68 patients could 
be followed up; 12 (20%) had recurrent syncope. 
Ventricular or supraventricular tachycardia was in-
ducible in 37 patients (35%). The frequency of organic 
heart disease was not higher in this group or in those 
with inducible ventricular tachycardia as compared with 
those with inducible supraventricular tachycardia. Three 
patients with inducible ventricular tachycardia died sud-
denly or were resuscitated from cardiac arrest, and an 
Although the etiology of syncope includes many disorders, 
the specific cause in an individual patient can usually be 
inferred from a carefully taken history, physical examination 
and noninvasive testing, and rational preventive measures 
may be prescribed. However, in an important subgroup of 
patients, this meticulous diagnostic approach yields no help-
ful information. Empirical therapy is often instituted with 
as much aggravation as mitigation of symptoms. 
Although cardiac arrhythmia is often a suspected cause, 
it is by nature of frequency not often documented by tem-
porary electrocardiographic monitoring. In addition, the 
finding of an asymptomatic arrhythmia is not conclusive 
because of the frequency of such arrhythmias in normal 
individuals. Recently, programmed electrical stimulation of 
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additional seven had recurrent syncope; thus, the total 
recurrence rate was 27 %. Of 23 patients undergoing 
effective therapy as predicted by electrophyslologic test-
ing, 3 (14%) had a recurrent event. Results were sig-
nificantly different in patients receiving ineffective ther-
apy as judged by electrophysiologic testing. Of 13 patients 
in this latter category, 7 patients (54%) had recurrence 
of syncope or cardiac arrest (p < 0.05). In three patients, 
recurrence took place a mean of 5 months after cessation 
of therapy; on resumption of effective therapy, no syn-
cope recurred for 15.6 months (p < 0.025). 
Tachycardia is frequently induced in patients with 
syncope of "nknown origin, whether. or not organic heart 
disease is present. Treatment of inducible tachycardia 
may prevent recurrence of syncope. 
(J Am Coli CardioI1985;5:216-23) 
the heart has been used to guide therapy in patients with 
documented but intermittent ventricular arrhythmias be-
cause the induced tachycardia correlates well with sponta-
neous tachycardia (1-3). Moreover, treatment of inducible 
ventricular tachycardia is predictive of long-term success in 
the prevention of spontaneous ventricular tachycardia with 
the same therapy (4-7). It follows that if syncope were 
caused by tachycardia and if the tachycardia were inducible 
with programmed electrical stimulation, the treatment of 
inducible tachycardia could prevent syncope. Therefore, we 
studied 105 patients with syncope of unknown origin to 
determine the frequency of inducible tachycardia and whether 
treatment of these tachycardias could prevent syncop'~. 
Methods 
Patients. All patients were referred to the University of 
Iowa Hospital or Veterans Administration Medical Center, 
Iowa City, for evaluation of syncope during the period from 
June 1979 to March 1983. Patients were selected for study 
if they had one or more episodes of syncope, the last of 
which occurred no more than 3 months before study. Among 
a total of 105 consecutive patients, 64 were male and 41 
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were female, ranging in age from 9 to 89 years (mean 60). 
Some patients had several episodes of syncope per month. 
Most patients, however, had either only one episode or 
episodes separated by many months. Initial evaluation in-
cluded a detailed history and physical examination, 15 lead 
electrocardiogram at rest, at least one 24 hour ambulatory 
electrocardiogram, neurologic evaluation and electroence-
phalography. Some patients also had a treadmill exercise 
test (66 patients), echocardiogram (62 patients) and cardiac 
catheterization (16 patients) when indicated by history or 
physical findings. These evaluations failed to provide an 
explanation for syncope. 
Electrophysiologic study. After informed consent was 
obtained, patients were studied in a postabsorptive nonse-
dated state. No patient had taken any cardiovascular drugs 
for at least five half-lives. With the Seldinger technique, 
two to four multipolar electrode catheters were placed in 
the heart through the femoral veins. Catheter positions in-
cluded high right atrium, His bundle. right ventricular apex 
and outflow tract and coronary sinus. In the atrial and ven-
tricular positions, the distal pair of electrodes on each cath-
eter was used for pacing, while the proxilnal pair was used 
for recoMing the local electrogram. Intracardiac and surface 
electrocardiograms were displayed on a multiple channel 
oscilloscope and recorded on paper at a speed of 100 mm/s. 
A programmable stimulator delivering constant current with 
a rectangular pulse (of 2 ms duration) at four times diastolic 
threshold was used. 
The stimulation protocol included: I) High right atrial 
pacing at incremental rates up to 200 beats/min to determine 
the sinus node recovery time and a maximal rate of 1: I 
atrioventricular (A V) conduction. 2) Premature atrial stim-
ulation with single and double extrastimuli during pacing 
at two or more basic cycle lengths for the evaluation of A V 
nodal function and the inducibility of supraventricular tachy-
cardia. In the four patients with evidence of pre-exci-
tation, coronary sinus pacing was performed also. 3) Right 
ventricular premature stimulation with single (S2) and dou-
ble (S2.S3) extrastimuli during right ventricular pacing (S)S)) 
at two or more basic cycle lengths (usually 600 and 400 
ms) from at least two right ventricular sites (usually outflow 
tract and apex). 4) Right ventricular burst pacing to a max-
imal rate of 250 beats/min for 10 to 15 complexes. 
In five patients, extrastimulus testing was undertaken 
from two or more left ventricular sites (usually apex and 
basal lateral free wall). In 10 patients. atrial or ventricular 
extrastimuli, or both. were repeated during isoproterenol 
infusion at a rate of 1.5 to 6 fLg/min. 
Definitions. As previously described (8), HV intervals, 
AH intervals, A V nodal refractory periods and sinus node 
recovery tim~s were measured. 
Supraventricular tachycardia. The mechanism of in-
duced suptaventricular tachycardia was considered to be A V 
nodal reentry if a discontinuous A V node function curve as 
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well as atrial echoes were demonstrated. Inducible supra-
ventricular tachycardia was classified as intraatrial reentrant 
tachycardia if surface P waves were not identical with sinus 
P waves and A V dissociation was present during tachycar-
dia. Reciprocating supraventricular tachycardia involving an 
extranodal A V pathway was considered to be present when 
eccentric atrial activation occurred during tachycardia and 
ventricular to atrial conduction occurred with premature 
ventricular stimuli when the His bundle was refractory. Ec-
topic supraventricular tachycardia was defined by a nonsinus 
P wave and eccentric atrial activation sequence during tachy-
cardia which was not initiated or terminated by extrastimuli. 
Ventricular tachycardia. This was defined as a wide QRS 
tachycardia with absent His bundle potentials (or HV in-
terval dissimilar to the patient's normal HV interval) and 
A V dissociation. When a I : 1 A V relation occurred during 
wide QRS tachycardia, ventricular tachycardia was inferred 
if there was no evidence for an extranodal A V pathway. 
Nonsustained ventricular tachycardia was defined as at least 
five consecutive nonpaced ventricular complexes that ter-
minated spontaneously. Sustained ventricular tachycardia 
required pacing or electrical cardioversion for termination. 
Polymorphic ventricular tachycardia was said to occur when 
the axis or bundle branch block configuration of QRS com-
plexes of induced tachycardia varied from cycle to cycle. 
Monomorphic ventricular tachycardia was said to exist when 
a uniform QRS configuration was induced despite QRS var-
iability in the initial tachycardia complexes after extrastimuli. 
Negative studies. Electrophysiologic studies were judged 
to be negative if fewer than five repetitive atrial or ventric-
ular responses, ventricular fibrillation alone or any nonre-
producible tachycardia (defined as occurring in less than 
two of five trials with the same stimulus intervals within 10 
ms) was induced. Using the protocol just described, the 
reproducibility criterion was always met in any patient with 
inducible tachycardia before antiarrhythmic therapy. 
Treatment. Ventricular tachycardia. All patients with 
inducible ventricular tachycardia underwent serial pro-
grammed electrical stimulation after the administration of 
incremental daily doses of procainamide (I to 3 g intrave-
nously or 6 to 12 g orally), quinidine (1,200 to 2,400 mg 
orally), disopyramide (600 to 1,200 mg orally), mexiletine 
(800 to 1,200 mg orally) or aprindine (100 mg orally) to 
assess whether the drugs prevented induction of tachycardia. 
Drug therapy was considered effective when sustained ven-
tricular tachycardia became nonsustained or noninducible. 
For nonsustained ventricular tachycardia, a drug was judged 
effective when ventricular tachycardia became noninducible 
(fewer than five nonstimulated complexes). All patients with 
sustained and non sustained ventricular tachycardia under-
went at least one antiarrhythmic drug trial. A serum drug 
concentration was determined after effectiveness was dem-
onstrated. When patients were given oral doses of the same 
drugs, serum levels were drawn before the next dose to 
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document mainentance of the same chronic drug level that 
was demonstrated during programmed electrical stimulation. 
Patients with tachycardia induced only during the infu-
sion of isoproterenol were considered effectively treated 
with either propranolol, 160 mg/day, or an equivalent dose 
of a comparable drug; these patients were not retested after 
beta-adrenergic blocking therapy. 
Supraventricular tachycardia. In general, patients with 
inducible supraventricular tachycardia were treated with in-
cremental daily doses of either propranolol (10 to 15 mg 
intravenously) or 160 to 240 mg orally); metoprolol (200 
mg orally), nadolol (160 to 240 mg orally) or verapamil (5 
to 15 mg intravenously or 240 to 480 mg orally). Five 
patients with supraventricular tachycardia underwent repeat 
programmed electrical stimulation after drug therapy, while 
others were simply given a therapeutic dose of a drug in-
dicated for such a tachycardia. 
Follow-up. Patients were followed up in clinic and by 
telephone as well as by conversation with the referring phy-
sician. Any witness who could give further information 
about syncopal episodes was also contacted. 
Statistics. Data were expressed as mean values ± stan-
dard error and were analyzed utilizing Fisher's exact test. 
Probability (p) values of less than 0.05 were considered to 
be statistically significant. 
Results 
Electrophysiologic findings. Of 105 patients, 37 (35%) 
had inducible tachycardia. Tables I and 2 show the types 
of tachycardia induced. In four patients, tachycardia was 
induced only during the infusion of isoproterenol. In four 
other patients, isoproterenol caused non sustained or non-
reproducible tachycardia to become sustained (supraven-
tricular tachycardia only) or reproducible. Six patients had 
sustained ventricular tachycardia that was monomorphic in 
four (in three patients the tachycardia had a right bundle 
branch block configuration and in one patient it had a left 
bundle branch block configuration). Twenty-two patients 
had nonsustained ventricular tachycardia that was mono-
morphic in 14 (in 10 with a right bundle branch block 
configuration and in four with a left bundle branch block 
configuration). Eight patients had non sustained polymorphic 
ventricular tachycardia. The shortest cycle lengths of the 
inducible tachycardia were as follows: 280 to 450 ms (mean 
335) for atrial tachycardia, 160 to 280 ms (mean 200) for 
nonsustained ventricular tachycardia and 180 to 260 ms 
(mean 227) for sustained ventricular tachycardia. 
Clinical features. The patients without inducible tachy-
cardia did not differ from patients with inducible tachycardia 
in terms of mean age, number of episodes of syncope before 
study, length of symptoms and follow-up period. The prev-
alence of women in the group with inducible tachycardia 
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(30%) was no different (p > 0.2) from that in the group 
with noninducible tachycardia (44%). There was no differ-
ence in the prevalence or type of heart disease between the 
two groups (Table 3). In addition, patients with inducible 
ventricular tachycardia were no more likely to have heart 
disease (18 of the 28) than were patients with inducible 
atrial tachycardia only (3 of 10) (p > 0.07) (Tables 1 and 
2). 
Ambulatory monitoring. Reexamination of previous am-
bulatory electrocardiographic recordings revealed that 5 (18%) 
of the 28 patients with ventricular tachycardia and 4 (31 %) 
of the 13 with supraventricular tachycardia had nonsustained 
episodes of asymptomatic tachycardia recorded. These ep-
isodes tended to be of shorter duration and slower rate than 
the induced episodes. Thus, an asymptomatic arrhythmia 
observed on ambulatory monitoring was of little help in 
predicting which patients might have tachycardia. 
Bradycardia (Table 4). Sixteen patients had rhythm and 
conduction system abnormalities suggesting that bradycar-
dia may have been responsible for their syncope (9-14). 
Management. Of the 13 patients with supraventricular 
tachycardia, therapy was prescribed as listed in Table 2. In 
5 of these 13, the effectiveness of drug therapy was doc-
umented during electrophysiologic testing. Of 28 patients 
with ventricular tachycardia, 19 had either complete supres-
sion of inducible tachycardia or induction of tachycardia 
only while they were receiving isoproterenol (Table I). 
Therapeutic levels measured at the time of testing varied 
among individual patients: for procainamide, levels were 
3.9 to 16 j.tg/ml; for propranolol, 60 to 100 ng/ml; for 
quinidine, 3.5 to 6 jLg/ml; for disopyramide, 2 to 6 j.tg/ml; 
for aprindine, 1.4 ng/ml and for phenytoin, 10 to 15 j.tg/ml. 
In two patients, nonsustained ventricular tachycardia ap-
peared to be facilitated by alcohol (Case 13) or phenytoin 
(Case 14). Treatment in both cases consisted only of ces-
sation of these agents. 
In seven patients, effective drugs were not identified for 
multiple reasons. In Patient 23, mUltiple trials with various 
drugs did not result in control of ventricular tachycardia; he 
was initially given 600 mg of amiodarone per day and not 
restudied (see later). In five (Cases 22 and 24 to 27), either 
the patient or the referring physician wished to try empirical 
or no therapy for inducible tachycardia. In Patient 28, further 
drug testing was not performed because sinus rhythm was 
recorded during a typical syncopal spell. This patient was, 
therefore, not given antiarrhythmic therapy and is not con-
sidered in further analysis since syncope definitely was not 
due to arrhythmia. 
Of the 16 patients whose syncope had a possible brady-
arrhythmic origin (Table 4), 6 with tachycardia were treated 
with antiarrhythmic drugs (Tables I and 2). Only one of 
these six had a permanent pacemaker implanted because of 
presumed drug exacerbation of sinus node disease (Case 29) 
(Table 2). 
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Table 1. Clinical Data in 28 Patients With Syncope and Inducible Ventricular Tachycardia 
Electrophysiologic Duration of Symptoms at 
Case Heart Disease Findings Treatment Follow-up (mo) Follow-up Comment 
Patients on Effective Therapy 
SSS NS MYT* (ISO); Nadolol 23 Syncope Recurrence at 21 mo 
1.5 s pause (Holter) 
2 WPW NS PYT Mexiletine 30 None 
3 None S PYT Procainamide 22 None 
4 Mitral prolapse S MYT Procainamide 44 None 
5 CAD NS PYT Procainamide 7 Sudden death 
6 None NS PYT. Procainamide 10 Syncope Recurrence at 8 mo; died 
3 s pause (CSM) of stroke 
7 Congenital NS MYT;* HY = 95 ms Aprindine 14 None Died of heart failure 
8 Mitral prolapse NS MYT Procainamide 24 None 
9 None NS PYT;* 2.7 s Disopyramide. 24 None 
pause (CSM) phenytoin 
lO CAD NS MYT; Quinidine 38 None 
3.9 s pause (CSM) 
II CAD S MYT Endocardial resection 36 None Not inducible after surgery 
12 CAD NS MYT Procainamide 18 None 
13 None NS MYT (alcohol) A voidance of alcohol 24 None 
14 Congenital NS MYT (phenytoin) Stop phenytoin 17 None 
15 Cardiomyopathy NS MYT (ISO) Nadolol; phenytoin 30 None 
16 None NS MYT (ISO) Propranolol 26 None 
Patients Not on Effective Therapy 
17 IYCD NS MYT (ISO) Propranolol 22 Syncope Recurrence at 4 mo on low dose; 
no recurrence at 18 mo on full 
dose 
18 CAD S MYT Procainamide 38 None On 50% of prescribed dose 
19 IVCD NS MYT Disopyramide 26 None Discontinued drug 
20 CAD NS PYT Quinidine Sudden death Inadequate dose 
21 None NS MYT Disopyramide 34 Syncope Recurrence at 16 mo off drug 
22 IYCD NS MYT* Propranolol t 12 None 
23 None S MYT Amiodarone. t 36 Cardiac arrest Occurrence 7 mo after stopping 
propranolol amiodarone; no recurrence on 
propranolol for 14 mo 
24 CAD NS MYT None 23 Syncope Recurrence at 18 mo 
25 None NS PYT Quinidinet 40 None 
26 None NS PYT Nadololt 21 None 
27 CAD. long QT NS PYT Propranolol t 24 None 
28 None S PYT None 5 Syncope Nonarrhythmic syncope; 
died of septic shock 
*In these patients. supraventricular tachycardia was also induced. tEfficacy of drug not tested. CAD = coronary artery disease; CSM = carotid 
sinus massage; ISO = isoproterenol infusion; IYCD = intraventricular conduction defect; MYT = monomorphic ventricular tachycardia; NS = 
nonsustained; PYT = polymorphic ventricular tachycardia; S = sustained; SSS = sick sinus syndrome; WPW = Wolff-Parkinson-White syndrome. 
Of the 68 patients without inducible tachycardia. 45 re-
ceived no treatment while 23 patients were managed em-
pirically on the basis of asymptomatic electrocardiographic 
findings. Empirical therapy included antiarrhythmic drugs 
(n = 3). beta-adrenergic blocking agents (n = 5). anti-
convulsant medication (n = 5), permanent pacemaker im-
plantation (n = 6) and discontinuation of potentially of-
fending drugs (n = 4). In this group, because the mechanism 
of syncope was not defined, there was no method to deter-
mine which drug or drug level would be effective in pre-
venting further symptoms. In general, however, levels of 
antiarrhythmic drugs were similar to the levels in patients 
with inducible tachycardia. 
FollOW-Up. Patients were followed up for a mean period 
of 25.8 months (range I to 45). None of the 60 patients in 
the group without inducible tachycardia died suddenly. 
Twelve patients in this group (20%) had recurrent syncope 
over an average follow-up period of 26.9 months. There 
was no significant difference (p > O. I) in recurrence rate 
between the empirically treated (21 %) and untreated (16%) 
groups. Syncope did not recur in the one patient in the 
empirically treated group who failed to comply with therapy. 
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Table 2. Clinical Data in 13 Patients With Syncope and Inducible Supraventricular Tachycardia 
Electrophysiologic Duration of Symptoms at 
Case Heart Disease Findings Treatment Follow-up (mo) Follow-up Comment 
SSS Ectopic (lSO);* Nadolol 23 Syncope Recurrence at 21 mo 
1.5 s pause (Holter) 
7 Congenital Intraatrial reentry* Aprindine 14 None Died of heart failure 
9 None Intraatrial reentry* Disopyramide;t 24 None 
phenytoin 
22 IVCD Intraatrial reentry* Propranolol 12 None 
29 SSS A VN reentry; Propranolol;t 30 Syncope No recurrence for 19 mo 
CSNRT = 650 ms pacemaker on drug; recurrence at 2 
mo off drug 
30 Mitral prolapse Intraatrial reentry (ISO) Nadolol 9 None 
31 None A VN reentry; SBP = 45 mm Hg Propranololt 27 None 
32 None A VN reentry (ISO) Nadolol 41 None 
33 None Ectopic (ISO) Metoprolol 24 None 
34 None AVN reentry Nadolol 35 None 
35 WPW Reciprocating with Verapamilt 19 Syncope Recurrence at 4 mo off 
accessory pathway; verapamil; no 
SBP = 60 mm Hg recurrence for 15 mo on 
diltiazem 
36 None A VN reentry (ISO) Nadolol 31 None 
37 None Intraatrial reentry; SBP = 40 Propranololt 29 None 
*Patient also had inducible ventricular tachycardia. tEfficacy of drug was tested. A VN = atrioventricular node; CSM = carotid sinus massage; 
CSNRT = corrected sinus node recovery time; ISO = isoproterenol infusion; IVCD = intraventricular conduction defect; SBP = systolic blood pressure 
(during tachycardia); SSS = sick sinus syndrome; WPW = Wolff-Parkinson-White syndrome. 
One patient in the untreated group had inducible ventricular 
fibrillation; this patient, followed up for 28 months until 
death caused by sepsis, had no recurrence of syncope. 
Inducible tachycardia group. Of 37 patients with in-
ducible tachycardia, all were followed up; 3 had an out of 
hospital cardiac arrest and 7 others had recurrence of syn-
cope. Thus, the total recurrence rate in this group was 27%. 
Patient 5 died suddenly, and Patients I and 6 had recurrent 
syncope while taking an adequate dose of effective drug as 
defined by programmed electrical stimulation. All other pa-
tients in this group had either stopped, decreased or changed 
effective drug therapy or, in the case of patients with ven-
tricular tachycardia, were given empirical therapy. Of the 
23 patients who adhered to the prescribed antiarrhythmic 
Table 3. Type of Heart Disease in 105 Patients With Syncope 
No Inducible Inducible 
Tachycardia Tachycardia 
No. (%) No. (%) 
None (n = 48) 32 (47) 16 (43) 
Coronary (n = 18) 10 (15) 8 (22) 
Electrical* (n = 20) 13 (19) 7 (19) 
Congenital/valvular (n = 8) 6 (9) 2 (5) 
Mitral valve prolapse (n = 6) 3 (4) 3 (8) 
Cardiomyopathy (n = 5) 4 (6) I (3) 
Total 68 (100) 37 (100) 
*Intraventricular conduction delay, sick sinus syndrome, Wolff-
Parkinson-White syndrome. 
therapy, only 14% had recurrent syncope or cardiac arrest. 
Of the 13 patients who did not adhere to therapy or received 
empirical treatment, 54% (Cases 17,20,21, 23, 24, 29 and 
35) had recurrent syncope or cardiac arrest (p < 0.05) (Table 
5). Moreover, Patients 17, 23 and 35 had no further syncope 
on resumption of effective antiarrhythmic therapy. In these 
three patients, the interval from discontinuance of therapy 
to recurrence of syncope (5 ± I months) was significantly 
shorter (p < 0.025) than the interval without recurrence of 
syncope during therapy (15.6 ± I months). 
Bradyarrhythmic group. Of the 16 patients with a pos-
sible bradyarrhythmic origin of syncope, 4 had recurrent 
syncope. Patient 29 had syncope recur only when not taking 
drugs and while the pacemaker was functioning well. Pa-
tients 1 and 6 were receiving antiarrhythmic therapy that 
was effective in preventing induction of their tachycardia; 
bradycardia may have been the cause for their recurrent 
Table 4. Patients With Syncope of Possible Bradyarrhythmic 
Origin (n = 16) 
Ambulatory monitoring 
Sinus pauses ranging from 1.5 to 7.5 s (n = 7) 
Carotid sinus massage 
Sinus pauses ranging from 2.7 to 4.7 s (n = 5) 
Electrophysiologic test 
A VN refractory period of 480 ms (n = I) 
HV intervals of 70 and 95 ms (n = 2) 
Corrected sinus node recovery time of 650 ms (n = I) 
AVN = atrioventricular node. 
l
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Table 5. Results of Treatment in 97 Patients With 
Long-Term Follow-up 
No inducible tachycardia (n = 60) 
Recurrent syncope while taking no medication 16% 
Recurrent syncope while taking empiric medication 21 % 
Inducible tachycardia (n = 37) 
Effecti ve therapy (n = 23) 
Recurrent syncope or cardiac arrest 140/c 
Ineffective therapy (n = 13) 
Recurrent syncope or cardiac arrest 54%* 
*p < 0.05 versus effective therapy group. 
syncope. Of the remaining 10 patients without inducible 
tachycardia, 6 had pacemakers; the only recurrence of syn-
cope occurred in I of the 6. 
Illustrative patient histories. Patient 2. This 47 year 
old woman had a long history of palpitation and known 
Wo1ff-Parkinson-White syndrome (type B). She presented 
with a history of four syncopal episodes over the course of 
2 months before admission. At electrophysiologic testing, 
only nonsustained polymorphic ventricular tachycardia was 
induced, which was suppressed by quinidine and later mex-
iletine. Syncope has not recurred. 
Patient 5. This 61 year old white woman with diabetes 
had a prior inferior wall myocardial infarction due to single 
right coronary artery disease. She presented with a single 
episode of syncope during the month before admission. 
Nonsustained polymorphic ventricular tachycardia was in-
duced with both right and left ventricular extrastimulus test-
ing. The tachycardia was suppressed with intravenous pro-
cainamide. She died suddenly 7 months later while taking 
appropriate doses of oral procainamide. 
Patient 23. This 64 year old man presented with a single 
episode of syncope during the month before admission. 
Sustained monomorphic ventricular tachycardia with right-
axis deviation and both a left and a right bundle branch 
block configuration was induced at rates up to 300 beats/min. 
It was not suppressed despite multiple doses of different 
drugs, which at times resulted in slower spontaneous epi-
sodes of the same tachycardia at rates of 150 beats/min 
associated with palpitation. In anticipation of surgical ther-
apy, cardiac catheterization and coronary angiography were 
performed and revealed essentially normal findings. The 
surgical approach was abandoned and the patient was em-
pirically treated with amiodarone, which only slowed epi-
sodes of nonsustained tachycardia. After 9 months of ther-
apy, the patient discontinued amiodarone because of 
pulmonary infiltration. Seven months later, he was resus-
citated from out of hospital ventricular fibrillation. Ven-
tricular tachycardia was again induced at electrophysiologic 
study, which was accelerated to 300 beats/min by isopro-
terenol. The patient has been asymptomatic for 14 months 
while taking propranolol. 
Patient 35. This 50 year old woman presented with an 
episode of syncope during the month before admission. 
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While type A pre-excitation was present on the electrocar-
diogram, no tachycardia was documented. Electrophysio-
logic study revealed only reciprocating supraventricular 
tachycardia with anterograde conduction over the A V node 
and retrograde conduction over the left free wall accessory 
pathway. Tachycardia was prevented after administration 
of 10 mg of intravenous verapamil. Because of edema, the 
patient stopped taking oral verapamil and syncope recurred 
4 months later. On reinstitution of diltiazem therapy, she 
has had no recurrence of syncope for 15 months. 
Discussion 
There are three major findings in this study. First, in-
ducible tachycardias are found in approximately one-third 
of patients with syncope of unknown origin. Second, in-
ducible tachycardias are equally common whether or not 
heart disease is present. However, inducible ventricular 
tachycardias, especially in patients with coronary artery dis-
ease, may identify a subgroup of patients with a predis-
position to cardiac arrest. Third, adherence to antiar-
rhythmic therapy guided by programmed electrical stimulation 
may prevent recurrence of syncope. 
Inducible tachycardias. Supraventricular tachycardia 
has been induced in patients with syncope of unknown origin 
in some (12, 15-18) but not all studies (19-21). The reason 
for this disparity in the frequency of inducible supraven-
tricular tachycardia is unclear; however, the number of pa-
tients in an individual report and the presence or absence 
of autonomic influences (22) may be factors (see Table 2). 
It may be questioned whether supraventricular tachycar-
dia can produce syncope, particularly in patients with rates 
that are not excessively fast. In some of our patients, systolic 
blood pressure frequently decreased to 40 to 60 mm Hg 
during supraventricular tachycardia in the supine position 
(Table 2). The mechanism to explain the decrease in arterial 
pressure has been considered in several studies (23-25). 
Ventricular tachycardia may also cause syncope, pre-
sumably as a result of hemodynamic alterations regardless 
of whether myocardial function is normal or abnormal (26). 
Ventricular tachycardia has been reported in 30 to 40% of 
patients with syncope of unknown origin by some investi-
gators (1,12,15,18-21,27), but not by others (16,17). This 
disparity may reflect differences in patient selection criteria; 
the latter investigators (16,17) studied only small groups of 
patients without demonstrable heart disease. 
When sustained ventricular tachycardia has been dem-
onstrated and long-term therapy is based on suppression 
during electrophysiologic testing, recurrent syncope appears 
to be prevented (12,19-21). At first glance, it is confusing 
that treatment of sustained ventricular tachycardia wbuld 
correlate well with prevention of syncope in some patients 
since the clinical episode must have been nonsustained if 
tachycardia were the cause of syncope. However, during 
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our electrophysiologic study, if tachycardia caused hemo-
dynamic instability, we artificially terminated it. Such 
tachycardia would be classified as "sustained" by our def-
inition, even though it might have subsequently stopped 
spontaneously. In any case, only 6 of 28 patients with ven-
tricular tachycardia and 6 of 13 with supraventricular tachy-
cardia had "sustained" tachycardia by our criteria. Thus, 
it is only in some patients that the definitions of sustained 
and nonsustained tachycardia at electrophysiologic study 
may cause confusion in understanding the mechanism of 
syncope. 
Logically, nonsustained ventricular tachycardia has been 
considered by many (12,18-20) to be the cause of unex-
plained syncope, although this conclusion is not universally 
accepted (21,27). It may be that non sustained tachycardia 
occurs frequently at electrophysiologic study because the 
studies are performed with the patient supine. Recent data 
suggest that a 60° tilt will cause supraventricular tachycardia 
to become sustained (25). This may also be the mechanism 
by which some ventricular tachycardias become nonsus-
tained since syncope may cause the patient to fall to the 
horizontal and terminate the tachycardia. 
However, nonsustained ventricular tachycardia induced 
during programmed electrical stimulation may also be a 
nonspecific finding in patients without clinical evidence for 
ventricular tachycardia (28). Careful examination of pre-
vious data (28,29) suggests that third and fourth extrastimuli 
produce nonclinical tachycardia that tends to be polymor-
phic. Even single and double ventricular premature stimuli 
produce nonclinical and non sustained ventricular tachycar-
dia in a ratio of 4: I (polymorphic: monomorphic, respec-
tively) (28). In the present study, only single and double 
premature stimuli were used to initiate tachycardia so as to 
limit false positive results. In contrast to a previous study 
of nonclinical ventricular tachycardia (28), nonsustained 
monomorphic ventricular tachycardia was induced in our 
study almost twice as frequently as nonsustained polymor-
phic ventricular tachycardia. Although nonsustained poly-
morphic ventricular tachycardia occurred infrequently, it 
was found in three of nine patients with recurrence of syn-
cope or sudden death. Two of these three patients had syn-
cope or died while taking adequate therapy as indicated by 
programmed stimulation (see Table I). Moreover, in two 
of the three patients with subsequent sudden death or cardiac 
arrest, nonsustained polymorphic ventricular tachycardia was 
induced, suggesting that nonsustained polymorphic ventric-
ular tachycardia in patients with syncope and coronary dis-
ease may indicate a predisposition to sudden death (30,31). 
Thus, nonsustained monomorphic or polymorphic ventric-
ular tachycardia induced in patients with syncope may rep-
resent their true clinical arrhythmia. 
One end pointfor antiarrhythmic therapy in patients with 
sustained ventricular tachycardia is the production of non-
sustained ventricular tachycardia « 15 complexes) (32). 
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Because patients with nonsustained tachycardia may have 
episodes of 15 complexes untreated, a different end point 
must be chosen for treatment of these patients, Previous 
studies (33-35) and the present study suggest that nonsus-
tained ventricular tachycardia may be treated successfully 
with drugs that produce fewer than five nonstimulated com-
plexes during electrophysiologic testing. 
Bradyarrhythmic group. In the present study, 16 pa-
tients had a possible bradyarrhythmic origin for their syn-
cope. Such data were obtained from asymptomatic 24 hour 
ambulatory recordings, electrophysiologic testing or carotid 
sinus massage (9-14). Of these 16 patients, 7 were asymp-
tomatic without pacemaker therapy, and pacemaker therapy 
was ineffective alone in preventing syncope in 2 of another 
7. In the light of this experience and the high prevalence 
of spontaneous resolution of syncope, we and others (21) 
continue to believe that asymptomatic bradyarrhythmias and 
isolated findings on electrophysiologic study or carotid sinus 
massage are not necessarily indications for pacemaker ther-
apy in syncope of unknown origin. 
Influence of gender or heart disease on inducibility of 
tachycardia. Heart disease was not found to be more com-
mon among patients with inducible tachycardia than in those 
without inducible tachycardia in this study; some of our 
patients without known heart disease had inducible ventric-
ular tachycardia (Table I). We do not believe that these 
ventricular tachycardias are artifacts of the testing procedure 
because of the considerations already discussed. Rather, 
since this study represents one of the largest long-term con-
secutive series of patients studied for syncope of unknown 
origin, it may be more reflective of the total group of patients 
with this syndrome. For the same reason, we believe our 
study did not show that female sex was predictive of a 
noninducible test (21). 
Effects of antiarrhythmic therapy. To prove that 
tachycardia is responsible for syncope, documentation of 
cardiac rhythm during episodes of loss of consciousness 
would be optimal. However, because of the sporadic nature 
of these events, such documentation cannot be obtained in 
most patients with routine or extended ambulatory electro-
cardiographic monitoring. The next best method to evaluate 
this hypothesis would be a prospective study of patients 
randomized to placebo or specific treatment based on the 
finding of inducible tachycardia alone. All investigations to 
date, including this study, have treated all patients who have 
inducible arrhythmias with presumed effective therapy. 
The findings from this and other studies must be viewed 
with the knowledge that many of our patients (up to 80%) 
and others (19,21,36) with syncope of unknown origin ap-
parently undergo spontaneous remission of their symptoms. 
In the present study, 13 patients were not receiving effective 
therapy for inducible tachyarrhythmia. In this group, the 
frequency of recurrent syncope or cardiac arrest was sig-
nificantly higher (54%) than in those patients receiving ef-
.
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fective therapy for the inducible tachycardia (14%), This 
suggests that although spontaneous remission may occur, 
antiarrhythmic drug therapy does prevent recurrent syncope 
in those with inducible tachycardia, These data support the 
view that tachyarrhythmias are responsible for syncope in 
some patients, Further studies are needed to definitely prove 
this hypothesis, 
We thank the staff of the cardiac catheterization laboratories at the Uni-
versity of Iowa for technical assistance in the conduct of these studies. 
Linda Bang and Jan Ellsworth provided secretarial assistance in the prep-
aration of this manuscript. 
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